Spotlight on EAS: Precision Lipid Management

Up Next

Spotlight on EAS: Precision Lipid Management

Average (ratings)
No ratings
Your rating
About the episode

Prof Fabian Demure discusses interim findings from the BE. REAL registry, a real-world study evaluating Inclisiran use in routine clinical practice. The conversation explores why additional real-world evidence was needed, how the enrolled population reflects patients with ASCVD seen in everyday care, and what the results show about LDL-C lowering, treatment persistence, safety, and tolerability.

Overview

This programme provides a focused spotlight on the latest developments and data presented at the European Atherosclerosis Society (EAS) Congress. Through a series of sessions, recorded at EAS and contributed by various faculty members, each offers concise analysis of late-breaking trial data, sub-analyses, and the clinical implications shaping contemporary lipid management.

 

Key Learning Objectives

  • Identify suitable patients for ApoC-III initiation using validated scoring parameters
  • Recall the most recent guidance for the use of ApoC-III inhibitor therapy
  • Discuss emerging clinical evidence of TG-lowering therapies across important trial sub-populations

Target Audience

  • Cardiologists
  • Lipidologists
  • Gastroenterologists
  • Endocrinologists
  • Other specialists associated with the management of familial chylomicronaemia syndrome (FCS)

More from this programme

Part 1

A Deep Dive Into the Data: Targeting ApoC-III Special Populations

The burden of hypertriglyceridemia (HTG) spans a broad and diverse patient population, from rare genetic disorders such as familial chylomicronaemia syndrome (FCS) to mixed hyperlipidaemia and familial dyslipidaemias. Current treatment strategies, including statins and fibrates, remain limited in their ability to adequately control triglyceride levels in many patients, highlighting the need for education around emerging therapeutic classes. ApoC-III–targeted therapies are demonstrating significant TG-lowering potential and are increasingly being evaluated across a wider range of patient populations, including those with FCS.


In this video, Dr Erin Michos (Johns Hopkins University School of Medicine, Baltimore, US) provides a deep dive into data presented at EAS 2026, targeting APOC-III in special populations.

 

This session is supported by an unrestricted educational grant from Arrowhead Pharmaceuticals.

1 session
A Deep Dive Into the Data: Targeting ApoC-III Special Populations Watch now

Part 2

In Context: A Peer-To-Peer Discussion on ApoC-III in Special Populations and Other Emerging Data

The burden of hypertriglyceridemia (HTG) spans a broad and diverse patient population, from rare genetic disorders such as familial chylomicronaemia syndrome (FCS) to mixed hyperlipidaemia and familial dyslipidaemias. Current treatment strategies, including statins and fibrates, remain limited in their ability to adequately control triglyceride levels in many patients, highlighting the need for education around emerging therapeutic classes. ApoC-III–targeted therapies are demonstrating significant TG-lowering potential and are increasingly being evaluated across a wider range of patient populations, including those with FCS.

 

In this video, Dr Michos (Johns Hopkins University School of Medicine, Baltimore, US) is joined by Dr Christie Ballantyne (Baylor College of Medicine, Houston, US) for an in-depth discussion on real-world implications and clinical decision-making around applying emerging guidance and evidence in severe hypertriglyceridemia and FCS. They review evolving guidelines and what emerging data tells us about managing complex patient populations.

 

This session is supported by an unrestricted educational grant from Arrowhead Pharmaceuticals.

1 session
In Context: A Peer-To-Peer Discussion on ApoC-III in Special Populations and Other Emerging Data Watch now

Part 3

EAS 2026 Data Highlights

Expert analysis of breaking congress data, highlighting key takeaways and impact on clinical practice.

8 sessions
EAS 2026 Data Highlights: Emerging Evidence on Targeted Therapies Watch now
EAS 2026 Data Highlights: Lp(a) and Residual Risk: Entering the HORIZON Era Watch now
EAS 2026 Data Highlights: A Look at Interim Results from the Heart-2 Study Watch now
EAS 2026 Data Highlights: Inclisiran Lipid Management and Muscle-Related Outcomes in VICTORION-Difference Watch now
EAS 2026 Data Highlights: Long-Term Inclisiran Effectiveness and LDL-C Goal Attainment in BE.REAL Watch now
EAS 2026 Data Highlights: Familial Hypercholesterolemia in Children and Adolescents: EAS Consensus Statement Watch now
EAS 2026 Data Highlights: EAS Consensus on Lipid Clinic Organisation and Funding Watch now
EAS 2026 Data Highlights: Oral PCSK9 Inhibition With Enlicitide: ApoB Effects Watch now

Faculty Biographies

Fabian Demeure

Fabian Demeure

Cardiologist

Prof Fabian Demeure is a Cardiologist at CHU UCL Namur, Yvoir, BE.

View full profile